Community perspectives on the benefits and risks of technologically enhanced communicable disease surveillance systems: a report on four community juries.
Data-linkage
Infectious disease
Pathogenomics
Public deliberation
Public health surveillance
Social licence
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
25 04 2020
25 04 2020
Historique:
received:
02
02
2020
accepted:
17
04
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
13
7
2021
Statut:
epublish
Résumé
Outbreaks of infectious disease cause serious and costly health and social problems. Two new technologies - pathogen whole genome sequencing (WGS) and Big Data analytics - promise to improve our capacity to detect and control outbreaks earlier, saving lives and resources. However, routinely using these technologies to capture more detailed and specific personal information could be perceived as intrusive and a threat to privacy. Four community juries were convened in two demographically different Sydney municipalities and two regional cities in New South Wales, Australia (western Sydney, Wollongong, Tamworth, eastern Sydney) to elicit the views of well-informed community members on the acceptability and legitimacy of: making pathogen WGS and linked administrative data available for public health researchusing this information in concert with data linkage and machine learning to enhance communicable disease surveillance systems Fifty participants of diverse backgrounds, mixed genders and ages were recruited by random-digit-dialling and topic-blinded social-media advertising. Each jury was presented with balanced factual evidence supporting different expert perspectives on the potential benefits and costs of technologically enhanced public health research and communicable disease surveillance and given the opportunity to question experts. Almost all jurors supported data linkage and WGS on routinely collected patient isolates for the purposes of public health research, provided standard de-identification practices were applied. However, allowing this information to be operationalised as a syndromic surveillance system was highly contentious with three juries voting in favour, and one against by narrow margins. For those in favour, support depended on several conditions related to system oversight and security being met. Those against were concerned about loss of privacy and did not trust Australian governments to run secure and effective systems. Participants across all four events strongly supported the introduction of data linkage and pathogenomics to public health research under current research governance structures. Combining pathogen WGS with event-based data surveillance systems, however, is likely to be controversial because of a lack of public trust, even when the potential public health benefits are clear. Any suggestion of private sector involvement or commercialisation of WGS or surveillance data was unanimously rejected.
Sections du résumé
BACKGROUND
Outbreaks of infectious disease cause serious and costly health and social problems. Two new technologies - pathogen whole genome sequencing (WGS) and Big Data analytics - promise to improve our capacity to detect and control outbreaks earlier, saving lives and resources. However, routinely using these technologies to capture more detailed and specific personal information could be perceived as intrusive and a threat to privacy.
METHOD
Four community juries were convened in two demographically different Sydney municipalities and two regional cities in New South Wales, Australia (western Sydney, Wollongong, Tamworth, eastern Sydney) to elicit the views of well-informed community members on the acceptability and legitimacy of: making pathogen WGS and linked administrative data available for public health researchusing this information in concert with data linkage and machine learning to enhance communicable disease surveillance systems Fifty participants of diverse backgrounds, mixed genders and ages were recruited by random-digit-dialling and topic-blinded social-media advertising. Each jury was presented with balanced factual evidence supporting different expert perspectives on the potential benefits and costs of technologically enhanced public health research and communicable disease surveillance and given the opportunity to question experts.
RESULTS
Almost all jurors supported data linkage and WGS on routinely collected patient isolates for the purposes of public health research, provided standard de-identification practices were applied. However, allowing this information to be operationalised as a syndromic surveillance system was highly contentious with three juries voting in favour, and one against by narrow margins. For those in favour, support depended on several conditions related to system oversight and security being met. Those against were concerned about loss of privacy and did not trust Australian governments to run secure and effective systems.
CONCLUSIONS
Participants across all four events strongly supported the introduction of data linkage and pathogenomics to public health research under current research governance structures. Combining pathogen WGS with event-based data surveillance systems, however, is likely to be controversial because of a lack of public trust, even when the potential public health benefits are clear. Any suggestion of private sector involvement or commercialisation of WGS or surveillance data was unanimously rejected.
Identifiants
pubmed: 32334597
doi: 10.1186/s12910-020-00474-6
pii: 10.1186/s12910-020-00474-6
pmc: PMC7183724
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
31Subventions
Organisme : National Health and Medical Research Council
ID : 1102962
Pays : International
Organisme : National Health and Medical Research Council (AU)
ID : 1083079
Pays : International
Références
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
Lancet Public Health. 2017 Aug;2(8):e348-e349
pubmed: 29253471
Health Expect. 2019 Jun;22(3):475-484
pubmed: 30714290
N Engl J Med. 2012 Jun 14;366(24):2267-75
pubmed: 22693998
Soc Sci Med. 2015 Apr;131:114-21
pubmed: 25770463
J Med Internet Res. 2018 Mar 28;20(3):e112
pubmed: 29592847
Pathology. 2015 Apr;47(3):199-210
pubmed: 25730631
BMJ. 2009 Mar 12;338:b866
pubmed: 19282440
J Infect. 2016 Sep;73(3):210-8
pubmed: 27311749
Soc Sci Med. 2017 Apr;179:166-171
pubmed: 28285232
Health Expect. 2017 Aug;20(4):626-637
pubmed: 27704684
PLoS One. 2016 Oct 13;11(10):e0163612
pubmed: 27737005
Asian Bioeth Rev. 2019;11(2):173-187
pubmed: 32218872
Epidemiol Infect. 2017 Jan;145(2):289-298
pubmed: 27780484
J Infect Dis. 2016 Dec 1;214(suppl_4):S421-S426
pubmed: 28830110
Foodborne Pathog Dis. 2018 Mar;15(3):161-167
pubmed: 29336594
Soc Sci Med. 2014 May;109:1-9
pubmed: 24657639
PLoS Comput Biol. 2015 Feb 09;11(2):e1003904
pubmed: 25664461
Hum Reprod. 2019 Apr 1;34(4):751-757
pubmed: 30865256
Wellcome Open Res. 2018 Jan 16;3:6
pubmed: 30854470
PeerJ. 2016 Apr 05;4:e1752
pubmed: 27069781
Science. 2004 Jan 30;303(5658):631-2
pubmed: 14752148
Nat Rev Genet. 2019 Jun;20(6):313-315
pubmed: 30874624
Euro Surveill. 2015 Apr 23;20(16):
pubmed: 25953273
Kennedy Inst Ethics J. 2012 Mar;22(1):1-33
pubmed: 22787956
BMC Med Res Methodol. 2013 Jun 04;13:72
pubmed: 23734773
Philos Technol. 2019;32(1):69-85
pubmed: 31024785
BMJ. 2019 Jan 30;364:l351
pubmed: 30700440
Nature. 2017 Apr 20;544(7650):309-315
pubmed: 28405027
Bull World Health Organ. 2018 Feb 1;96(2):129-134
pubmed: 29403116
J Infect Dis. 2016 Dec 1;214(suppl_4):S375-S379
pubmed: 28830113
Public Underst Sci. 2012 Jul;21(5):556-72
pubmed: 23823165
Emerg Infect Dis. 2014 Aug;20(8):1306-14
pubmed: 25062035
Health Res Policy Syst. 2019 Apr 4;17(1):35
pubmed: 30947721
Nature. 2009 Feb 19;457(7232):1012-4
pubmed: 19020500
J Biomed Inform. 2019 Jun;94:103181
pubmed: 31014979
PLoS One. 2011;6(12):e28071
pubmed: 22164229
Int J Med Inform. 2006 Jul;75(7):530-41
pubmed: 16198142
J Am Med Inform Assoc. 2007 Nov-Dec;14(6):706-12
pubmed: 17712084
Soc Sci Med. 2007 Jan;64(1):223-35
pubmed: 17045717
Sci Am. 2008 Sep;299(3):64-9
pubmed: 18783053
PLoS One. 2015 Oct 05;10(10):e0139701
pubmed: 26437454
Infect Dis Health. 2019 Feb;24(1):44-48
pubmed: 30541697
Public Underst Sci. 2014 Jan;23(1):48-52
pubmed: 24434712
Nat Rev Microbiol. 2007 Jun;5(6):464-70
pubmed: 17487146
J Infect Dis. 2016 Feb 15;213(4):502-8
pubmed: 25995194
Clin Microbiol Infect. 2017 Feb;23(2):69-72
pubmed: 27642177
JAMA Intern Med. 2013 Oct 28;173(19):1798-806
pubmed: 23958803
Science. 2014 Mar 14;343(6176):1203-5
pubmed: 24626916
PLoS Curr. 2015 Feb 10;7:
pubmed: 25713745
Soc Sci Med. 2011 Aug;73(3):367-74
pubmed: 21726926
Euro Surveill. 2014 Aug 07;19(31):6-13
pubmed: 25138971
Nat Rev Genet. 2018 Jan;19(1):9-20
pubmed: 29129921
Infect Dis Rep. 2016 Jun 24;8(2):6570
pubmed: 27403269
J Epidemiol Community Health. 2011 Feb;65(2):150-6
pubmed: 19948532
PLoS Med. 2015 Dec 03;12(12):e1001921
pubmed: 26633831
Am J Public Health. 2012 Jan;102(1):38-44
pubmed: 22095338